Sasanlimab

DRUG19 trials

Sponsors

Seagen Inc., Pfizer, The Methodist Hospital Research Institute, National Cancer Institute (NCI), NiKang Therapeutics, Inc.

Conditions

AdenocarcinomaAdvanced Clear Cell Renal Carcinoma (Ccrcc)Advanced Clear Cell Renal Cell CarcinomaAdvanced Renal Cell CarcinomaAdvanced Solid TumorsAdvanced or Metastatic Solid TumorsBladder CancerCarcinoma

Phase 1

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

TerminatedNCT04254107

Seagen Inc.Bladder Cancer, Cervical Cancer, Classical Hodgkin Lymphoma +9

Start: 2020-05-29End: 2023-12-01Updated: 2025-02-10

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

TerminatedNCT04458259

PfizerNeoplasm Metastasis

Start: 2020-09-24End: 2024-11-15Updated: 2025-08-28

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

TerminatedNCT04585815

PfizerCarcinoma, Non-Small-Cell Lung

Start: 2020-11-10End: 2024-10-29Updated: 2026-01-09

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

TerminatedNCT05061537

PfizerBladder Cancer, Colorectal Cancer, Head and Neck Cancer +7

Start: 2021-10-20End: 2022-10-14Updated: 2024-04-12

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

TerminatedNCT05233436

PfizerAdvanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer +3

Start: 2022-02-24End: 2023-10-16Updated: 2026-02-19

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

WithdrawnNCT05259397

PfizerBladder Cancer

Start: 2022-03-24End: 2022-09-19Updated: 2023-03-08

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

RecruitingNCT05665361

National Cancer Institute (NCI)Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)

Start: 2024-04-24End: 2027-06-01Target: 100Updated: 2026-03-09

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

TerminatedNCT06285097

PfizerColorectal Carcinoma, Melanoma, Neoplasms +5

Start: 2024-02-08End: 2025-02-13Updated: 2025-09-17

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

TerminatedNCT06448364

PfizerAdvanced or Metastatic Solid Tumors, Colorectal Cancer, Melanoma +2

Start: 2024-05-09End: 2024-08-15Updated: 2024-11-06

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

TerminatedNCT06546553

PfizerColorectal Carcinoma, Neoplasms, Non-small-cell Lung Cancer +3

Start: 2024-09-06End: 2025-10-03Updated: 2026-02-23

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

TerminatedNCT06580938

PfizerBladder Cancer, Colorectal Cancer, Head and Neck Cancer +3

Start: 2024-11-11End: 2025-07-14Updated: 2026-03-23

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Active, not recruitingNCT06704724

PfizerCarcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Colorectal Neoplasms

Start: 2024-12-10End: 2029-03-11Updated: 2026-03-13

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Active, not recruitingNCT06870487

PfizerClassical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Head and Neck Squamous Cell Carcinoma +3

Start: 2025-05-08End: 2026-04-26Target: 6Updated: 2026-04-01

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Active, not recruitingNCT06974734

PfizerCarcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma +1

Start: 2025-05-06End: 2026-04-30Updated: 2026-03-19

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

RecruitingNCT07206225

PfizerNon-muscle Invasive Bladder Cancer

Start: 2025-11-06End: 2033-01-28Target: 294Updated: 2026-03-11

Phase 2

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Active, not recruitingNCT05241340

The Methodist Hospital Research InstituteUrothelial Carcinoma Bladder

Start: 2022-02-15End: 2027-04-01Target: 33Updated: 2025-10-24

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

TerminatedNCT05935748

NiKang Therapeutics, Inc.Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma +18

Start: 2023-07-28End: 2025-09-04Updated: 2025-11-12

Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

Not yet recruitingNCT06218069

Radboud University Medical CenterNSCLC

Start: 2025-02-28End: 2027-03-31Target: 20Updated: 2024-11-29

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

RecruitingNCT07123090

Stephanie BergAdvanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Metastatic Renal Cancer +3

Start: 2025-11-24End: 2028-02-01Target: 25Updated: 2026-03-25

Related Papers

Abstract 1672: Enhanced delivery and activity of a novel antibody-drug conjugate, PF-08052667, for treatment of non-muscle invasive bladder cancer

Cancer Research2026-04-03

Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer

Journal of Medicinal Chemistry2024-12-0913 citations

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Abstract CT265: Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies

Cancer Research2023-04-144 citations

Abstract 6361: A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody

Cancer Research2023-04-044 citations

Abstract 5668: Using clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)

Cancer Research2023-04-042 citations

Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma—A phase 1, open-label, pharmacokinetic, safety and tolerability study.

Journal of Clinical Oncology2023-02-204 citations

Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.

Journal of Clinical Oncology2023-01-24

1367 A highly-selective HPK1 inhibitor enhances T cell receptor signaling and T cell activation potential, increasing antigen recognition and efficacy of PD-1 therapy

Regular and Young Investigator Award Abstracts2022-11-01

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC).

Journal of Clinical Oncology2022-06-011 citations

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

Regular and Young Investigator Award Abstracts2021-11-011 citations

456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress

Regular and Young Investigator Award Abstracts2021-11-011 citations

SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).

Journal of Clinical Oncology2021-05-209 citations

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

Journal of Clinical Oncology2021-05-205 citations

250 SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc? R engagement

Regular and Young Investigator Award Abstracts2020-11-013 citations